SynthesisPituitary2025
The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis.
Synthesis in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study.Endocrine connections · 2026Article
- Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Craniopharyngioma - What's next.Pituitary · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeCraniopharyngiomas (CPs) cause hypopituitarism in most patients, with growth hormone deficiency (GHD) being the most prevalent form. Growth hormone replacement therapy (GHRT) is the standard treatment for GHD, but the impact of this therapy on CP recurrence remains unclear. This study aimed to evaluate the effect of GHRT on CP recurrence in both pediatric and adult populations.
methodsThe PubMed, Cochrane Library, Web of Science, Embase and ClinicalTrials.gov databases were systematically searched in accordance with the 2020 PRISMA guidelines. Original studies comparing the impact of GHRT and non-GHRT on CP recurrence were included. Among the 817 initially identified records, 12 studies met the inclusion criteria. Two independent investigators extracted the data and assessed the quality of the included studies.
resultsThe meta-analysis revealed that GHRT significantly reduced the risk of recurrence (OR = 0.56, 95% CI 0.41-0.77). Subgroup analyses revealed that GHRT had a more significant effect among patients with a follow-up period of more than five years. Initiating GHRT within 12 months after CP treatment significantly reduced the recurrence rate (OR = 0.32, 95% CI 0.16-0.62). Sensitivity analyses and publication bias tests revealed that the results were robust.
conclusionsThe meta-analysis shows that GHRT does not increase the risk of recurrence in CP, even when initiated within 12 months postoperatively. GHRT should be considered an essential treatment for CP patients with GHD.
Indexed as
Identifiers
41047428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.